Navigation Links
Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
Date:10/6/2011

LAS VEGAS, Oct. 6, 2011 /PRNewswire/ -- This is being released by SCM:

(Photo:  http://photos.prnewswire.com/prnh/20111006/LA81891)

After 7 weeks of testimony and 4 hours of closing statements, lead trial attorney for the plaintiffs in the hepatitis C trial in Clark County Nevada, Robert Eglet, asked jurors to bring a verdict of $10 million in compensatory damages for Anne Arnold, $2.5 million in compensatory damages for James Arnold and to consider whether the Arnolds should receive punitive damages. 

Attorney Robert Eglet told jurors, corporate greed dictated the actions of the drug company Teva Pharmaceuticals. "The primary concern should be the safety of the patient. A responsible drug company should design, package and market the drug to reduce human error. The drug companies knew there was a problem with the jumbo infusion 50mL vials of Propofol in these endoscopy centers," said Eglet.

Eglet told jurors that every 50mL vial of Propofol was sent to the endoscopy centers with a vent spike labeled for multi dosing.  "The temptation and opportunity is too great for misuse and the drug company knew this. They took no steps to prevent this. They did nothing and Teva expert witnesses Craig Lea and Rosalie Lowe in depositions agreed that health care providers using 50mL vials in an endoscopy center create more of a proclivity to multi dose," said Eglet.  

Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admitted under examination by Eglet that Teva turned the lights out in their Propofol plant 21 days after last year's verdict. 

The jury is now in deliberation.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor.


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved ... are expected to be developed in coming years. Many ... techniques. Cancer stem cell therapies are also expected to ...
(Date:5/3/2016)... , May 3, 2016  As a teenager, an ... rheumatic fever, which damaged his heart. He continued enjoying ... by June 2013, Shepherd,s heart was giving out and ... On June 20, 2013, the Mesa, Arizona ... Heart (TAH-t). Like a heart transplant, the SynCardia TAH-t ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK , ... today announced Food and Drug Administration (FDA) approval ... that provides heart failure patients with access to ... also have remote monitoring with daily automatic transmission ... heart rate in response to physiological demands. ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... 2016 , ... Every year 220 Mississippi kids are diagnosed ... children. The wishes provide hope and motivation through positive experiences while they ... Brent Wilson said, “In 2016, the organization will grant 50% of wishes deemed ...
(Date:5/5/2016)... ... May 05, 2016 , ... Long Island’s fastest growing comprehensive ... noted Long Island eye surgeon, Kathleen Van Valkenburg, MD as part of their ongoing ... Martin, MD, medical director and managing partner of North Shore Eye Care. , ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TIME for ... safety – today announced a new partnership to reach nearly 1 million children with ... in an instant and is the leading cause of accidental death in children one ...
(Date:5/5/2016)... , ... May 05, 2016 , ... In honor of ... is encouraging people all over the United States to thank a nurse who's made ... Healthcare will donate $5 to the American Red Cross of San Diego/Imperial Counties (up ...
(Date:5/5/2016)... ... ... will celebrate its three-year anniversary on May 14 by giving away a free treatment ... To date, the Lung Institute has treated over 2,000 people at their five clinics across ... success of this treatment and to the patients who refuse to give up,” says Lung ...
Breaking Medicine News(10 mins):